1 Biotech + 2 Cancer Drugs = 100% Pop
Shares of the small-cap biotech Clovis Oncology soared after presenting data on two drugs -- one for lung cancer and another that's tied to the same genetically defective BRCA function that made Angelina Jolie decide to get a double mastectomy.
That would be rucaparib, the PARP inhibitor Clovis licensed from Big Pharma Pfizer. The class of drugs had a big showing at the ASCO conference and caused a number of big pops and drops today.
The unexpectedly strong data for early stage lung cancer drug CO-1686 surprised investors. As potentially the first treatment for those with the T790M mutation, this could be an incredibly important product.
In this video, health-care analyst David Williamson discusses what these events mean for investors in Clovis and also for its competitors.
Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report "Everything You Need to Know About Obamacare" lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.
The article 1 Biotech + 2 Cancer Drugs = 100% Pop originally appeared on Fool.com.David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.